{"product_id":"diagnostic-pathology-lymph-nodes-and-extranodal-lymphomas-hardback-9780323847582","title":"Diagnostic Pathology: Lymph Nodes and Extranodal Lymphomas (Hardback) 9780323847582","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eDiagnostic Pathology: Lymph Nodes and Extranodal Lymphomas\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eExpert, up-to-date coverage of benign and malignant lesions of lymph nodes, spleen, and extranodal lymphomas\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eL. Jeffrey Medeiros (Author), Roberto N. Miranda (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780323847582\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 5 January 2023\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e975 pages, \u003cp\u003eContains \u003cb\u003emore than 3,100 \u003c\/b\u003ehigh-quality clinical and histologic images, gross pathology images, radiologic images, micrographs, flow cytometry histograms, and full-color illustrations\u003c\/p\u003e\n\u003cbr\u003e27.6 x 21.6 x 4.6 cm, 3.19 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003ci\u003e\"This book is part of the Diagnostic Pathology Series, covering benign and malignant lesions of lymph nodes, as well as extranodal lymphomas. This third edition has been updated from the previous version, published in 2017, according to the most recent fifth edition of the WHO Classification of Hematolymphoid Tumors.\"\u003c\/i\u003e ©Doody’s Review Service, 2023 Anamarija Perry, MD (University of Michigan Medical School) \u003cb\u003eDoody's Score: 5 Stars!\u003c\/b\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThis expert volume in the \u003ci\u003eDiagnostic Pathology\u003c\/i\u003e series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering all aspects of benign and malignant lesions of lymph nodes and extranodal and splenic lymphomas, it incorporates the most recent clinical, pathological, and molecular knowledge in this challenging field to provide a comprehensive overview of all key issues relevant to today’s practice. Richly illustrated and easy to use, \u003ci\u003eDiagnostic Pathology: Lymph Nodes and Extranodal Lymphomas\u003c\/i\u003e, third edition, is a one-stop reference for accurate, complete pathology reports, ideal as a day-to-day reference or as a reliable training resource.\u003cul\u003e \u003cli\u003e  \u003cp\u003ePresents concise, extensive, and up-to-date information on more than 120 benign and malignant lesions of the lymph nodes, and covers extranodal lymphomas to help new and experienced surgical pathologists and hematopathologists alike identify crucial elements of each diagnosis and associated differential diagnoses \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eProvides clinical and histologic features, results of relevant ancillary studies, and a differential diagnosis for each entry \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eFeatures extensive updates throughout, reflecting the increasing importance of molecular markers for more precise diagnoses, and covering newly defined disease entities \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eIncludes new chapters covering EBV(+) T- and NK-cell lymphoproliferative disorders of childhood, Erdheim-Chester disease, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, primary cutaneous acral CD8(+) lymphoma, primary cutaneous CD4(+) small\/medium T-cell lymphoproliferative disorder, and primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma; also provides new information on breast implant-associated anaplastic large cell lymphoma \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eContains more than 3,400 high-quality clinical and histological images, gross pathology images, radiologic images, micrographs, flow cytometry histograms, and full-color illustrations to help practicing and in-training pathologists reach a confident diagnosis \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eIncludes updated criteria, terminology, and classifications using the WHO Classification of Hematolymphoid Tumors: Lymphoid Neoplasms, 5th edition  \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eEmploys consistently templated chapters, bulleted content, key facts, a variety of test data tables, annotated images, and an extensive index for quick, expert reference at the point of care \u003c\/p\u003e\n\u003c\/li\u003e \u003cli\u003e  \u003cp\u003eIncludes an eBook version that enables you to access all text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud \u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eSECTION 1: REACTIVE NONSPECIFIC CHANGES\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e4 Reactive Follicular Hyperplasia\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e10 Reactive Paracortical Hyperplasia\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e \u003cp\u003eSECTION 2: INFECTIOUS CAUSES OF LYMPHADENITIS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e20 Chronic Granulomatous Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e28 Suppurative Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e32 \u003ci\u003eMycobacterium tuberculosis \u003c\/i\u003eLymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e40 Atypical Mycobacterial Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e48 Mycobacterial Spindle Cell Pseudotumor\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e52 Cat-Scratch Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e58 Bacillary Angiomatosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e64 Lymphogranuloma Venereum Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e68 Whipple Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e72 Syphilitic Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e78 Infectious Mononucleosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e84 \u003ci\u003eHistoplasma \u003c\/i\u003eLymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e90 \u003ci\u003eCryptococcus \u003c\/i\u003eLymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e94 \u003ci\u003eToxoplasma \u003c\/i\u003eLymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e100 \u003ci\u003eCoccidioides \u003c\/i\u003eLymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e106 Herpes Simplex Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e112 Cytomegalovirus Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e120 Human Immunodeficiency Virus Lymphadenitis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e \u003cp\u003eSECTION 3: REACTIVE LYMPHADENOPATHIES\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e132 Inflammatory Pseudotumor of Lymph Node\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e140 Progressive Transformation of Germinal Centers\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e146 Kikuchi-Fujimoto Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e156 Rosai-Dorfman Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e166 Kimura Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e174 Unicentric Hyaline-Vascular Variant Castleman Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e182 Unicentric Mixed\/Plasmacytic Variant Castleman Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e188 Multicentric Castleman Disease, Idiopathic\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e196 Multicentric Castleman Disease, HHV8 Associated\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e204 Rheumatoid Arthritis-Related Lymphadenopathy\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e212 Sarcoid Lymphadenopathy\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e218 Dermatopathic Lymphadenopathy\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e224 Hemophagocytic Lymphohistiocytosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e234 Lymphadenopathy Associated With Joint Prostheses\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e240 Lipid-Associated Lymphadenopathy\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e244 Lymphadenopathy Secondary to Drug-Induced Hypersensitivity Syndrome\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e254 IgG4-Related Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e264 Systemic Lupus Erythematosus\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e270 Sinus Histiocytosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e \u003cp\u003eSECTION 4: HODGKIN LYMPHOMAS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e278 Nodular Lymphocyte-Predominant Hodgkin Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD \u003cb\u003e290 Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Tables\u003c\/b\u003e\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e292 Lymphocyte-Rich Classic Hodgkin Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e300 Nodular Sclerosis Hodgkin Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e310 Mixed Cellularity Hodgkin Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e316 Lymphocyte-Depleted Hodgkin Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 5: LEUKEMIA\/LYMPHOMAS OF IMMATURE B- OR T-CELL LINEAGE\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e324 B-Lymphoblastic Leukemia\/Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e334 T-Lymphoblastic Lymphoma\/Leukemia\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 6: NODAL B-CELL LYMPHOMAS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e346 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e356 Richter Transformation\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e364 Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e374 Nodal Marginal Zone Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e380 Nodal Follicular Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e392 Pediatric-Type Follicular Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e396 Mantle Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e404 Mantle Cell Lymphoma, Blastoid and Pleomorphic Variants\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e412 Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e422 T-Cell\/Histiocyte-Rich Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e428 ALK(+) Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e434 EBV(+) Diffuse Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e442 HHV8(+) Diffuse Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e450 Burkitt Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e460 High-Grade B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e468 Mediastinal Gray Zone Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 7: EXTRANODAL B-CELL LYMPHOMAS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e480 Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e494 Extranodal Follicular Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e506 Primary Cutaneous Follicle Center Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e516 Primary Mediastinal (Thymic) Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e526 Primary Diffuse Large B-Cell Lymphoma of Central Nervous System\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e536 Pyothorax-Associated Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e542 Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e550 Plasmablastic Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e560 Primary Effusion Lymphoma and Solid Variant of Primary Effusion Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e570 Lymphomatoid Granulomatosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e580 Intravascular Large B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e586 Plasmacytoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e594 EBV-Positive Large B-Cell Lymphoma Associated With Breast Implants\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e600 Primary Diffuse Large B-Cell Lymphoma of Testis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e608 Splenic Marginal Zone Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e616 Hairy Cell Leukemia\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD, Mario L. Marques-Piubelli, MD, and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e624 Hairy Cell Leukemia Variant\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD, Mario L. Marques-Piubelli, MD, and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e632 Splenic Diffuse Red Pulp B-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD, Mario L. Marques-Piubelli, MD, and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e638 Diffuse Large B-Cell Lymphoma Arising in the Spleen\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 8: NODAL T-CELL LYMPHOMAS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e646 Peripheral T-Cell Lymphoma, Not Otherwise Specified\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e656 Angioimmunoblastic T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e666 Adult T-Cell Leukemia\/Lymphoma, HTLV-1(+)\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e676 ALK(+) Anaplastic Large Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e684 ALK(-) Anaplastic Large Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 9: EXTRANODAL NK-\/T-CELL LYMPHOMAS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e694 Breast Implant-Associated Anaplastic Large Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e706 Extranodal NK-\/T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e716 Hepatosplenic T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD, Mario L. Marques-Piubelli, MD, and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e726 Enteropathy-Associated T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e734 Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e742 Indolent T-Cell Lymphoma of the Gastrointestinal Tract\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e748 Subcutaneous Panniculitis-Like T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e756 T-Cell Prolymphocytic Leukemia Involving Lymph\u003c\/p\u003e \u003cp\u003e\u003ci\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/i\u003e\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e766 Primary Cutaneous ?\/d T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e774 EBV(+) T- and NK-Cell Lymphoid Proliferations and Lymphomas of Childhood\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e784 Mycosis Fungoides\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e798 Sézary Syndrome\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e810 Primary Cutaneous Anaplastic Large Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e818 Lymphomatoid Papulosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e826 Primary Cutaneous Acral CD8(+) Lymphoproliferative Disorder\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e832 Primary Cutaneous CD8(+) Aggressive\u003c\/p\u003e \u003cp\u003eEpidermotropic Cytotoxic T-Cell Lymphoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e840 Primary Cutaneous CD4(+) Small\/Medium T-Cell Lymphoproliferative Disorder\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 10: IMMUNODEFICIENCYASSOCIATED LYMPHOPROLIFERATIONS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e846 Overview of Primary Immunodeficiency-Associated Lymphoproliferative Disorders\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e852 Autoimmune Lymphoproliferative Syndrome\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e864 Immunomodulating Agent-Associated Lymphoproliferative Disorders\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e872 Posttransplant Lymphoproliferative Disorders, Nondestructive Lesions and Polymorphic\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e882 Posttransplant Lymphoproliferative Disorder, Monomorphic\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e892 EBV(+) Mucocutaneous Ulcer\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 11: GRANULOCYTIC\/HISTIOCYTIC TUMORS\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e898 Myeloid Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e906 Blastic Plasmacytoid Dendritic Cell Neoplasm\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e914 Blastic T\/Myeloid Neoplasm With Rearrangements of \u003ci\u003eFGFR1\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e924 Cutaneous Mastocytosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e928 Systemic Mastocytosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e940 Histiocytic Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e950 Follicular Dendritic Cell Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e958 Interdigitating Dendritic Cell Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e964 Langerhans Cell Histiocytosis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e976 Langerhans Cell Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e984 Erdheim-Chester Disease\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e \u003cp\u003eSECTION 12: NONHEMATOPOIETIC PROLIFERATIONS IN LYMPH NODE\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e990 Epithelial Inclusions in Lymph Node\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e996 Nevus Cell Inclusions in Lymph Node\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e1000 Vascular Transformation of Lymph Node Sinuses\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e1004 Angiomyomatous Hamartoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e1008 Palisaded Myofibroblastoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eL. Jeffrey Medeiros, MD and Roberto N. Miranda, MD\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e1012 Metastatic Kaposi Sarcoma\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRoberto N. Miranda, MD and L. Jeffrey Medeiros, MD\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Pathology [\u003ca title=\"See our other books on Pathology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pathology%20%5BMMF%5D%22\"\u003eMMF\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Freshly Printed Books","offers":[{"title":"Default Title","offer_id":46648094523672,"sku":"9780323847582","price":185.99,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780323847582.jpg?v=1694992169","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/diagnostic-pathology-lymph-nodes-and-extranodal-lymphomas-hardback-9780323847582","provider":"Freshly Printed Books","version":"1.0","type":"link"}